Home › Free Stock Grades › CCCC
C4 Therapeutics, Inc. (CCCC) Stock Grade
CCCC · Healthcare
C
Market Cap
$344.4M
P/E Ratio
—
Revenue Growth (YoY)
+1.0%
Net Margin
-292.1%
Return on Equity
—
Dividend Yield
None
About C4 Therapeutics, Inc.'s fundamentals
C4 Therapeutics is a biotechnology company with a market capitalization of $344.4 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -292.1%. The company generated minimal revenue growth of just 1.0% year-over-year, indicating stagnant top-line expansion. As a pre-profitable biotech firm, C4 Therapeutics does not pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not meaningful given the company's loss-making status.